Loading…
← CockpitCompetitor Analysis › ELAN Elanco Animal Health, Inc.Open in the cockpit ↗

Elanco Animal Health, Inc.ELANCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Global animal health company selling medicines and vaccines for pets and farm livestock, spun off from Eli Lilly.

Momentum leader 90
Mkt cap
$13.3B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$135M
20-day average traded
Fwd P/E
21.5×
forward earnings
ROIC−WACC
-8.8 pp
WACC 12.0%
Hurdle
+25 pp
Req g minus delivered
Official | Implied
BB- / BBB-
agencies · bond market
Next earnings
104 days
2 Mar 2027
Close · USD$26.70
1D+3.3%
1W+0.8%
1M+17.6%
3M+13.3%
6M+28.1%
YTD+18.0%
1Y+24.6%
ATR %3.6%
Beta1.33
52w lowhigh4.6% off high

What Elanco Animal Health does

Global animal health company selling medicines and vaccines for pets and farm livestock, spun off from Eli Lilly.

Sells through veterinary clinics and animal-health distributors, with pet products the faster-growing side and farm-animal products the slower, farm-economics-tied side. The 2020 purchase of Bayer's animal health unit added the Seresto flea-and-tick collar to its pet range.

Products and services

  • Pet health (parasiticides, pain, dermatology)
  • Farm animal (livestock health/productivity)
  • Vaccines (companion and farm animal)

Customers

  • Veterinarians
  • Farmers/livestock producers
  • Pet owners via the vet channel

Where it sits in the supply chain

  • Healthcare
  • Animal health
  • Veterinary pharmaceutical and vaccine…

What could go right

  • Pet health category growth (humanization of pets)
  • New product launches and pipeline conversion

What could go wrong

  • High debt load from Bayer Animal Health acquisition
  • Livestock segment commodity/farm-economics sensitivity

Moat: narrow (brand, distribution, regulatory licence). Established veterinary brand relationships and regulatory approvals across species create switching costs.

Headquarters: Greenfield, Indiana, US · Founded: 2018 · Employees: 9,900

Named competitors

Elanco Animal Health at a glance

Size Elanco Animal Health (ELAN) is a United States Health Care company (Biotechnology) with a market value of $13.3B, the 648th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.70 on 18 Nov 2026.

Performance Over six months the shares gained 28.1%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 12.1% over the last twelve months (peer median +25.6%); the operating margin is 7.6% (peer median 15.8%).

Valuation It trades at 21.5× forward earnings against a peer median of 30.5× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.8 points below its cost of capital (12.0% WACC).

Credit Elanco Animal Health has 1 bond outstanding ($732M), rated BB- by the agencies and trading like BBB- at a weighted spread of 101 bp.

Short interest Short interest is 6.6% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026ELAN 125Peer median 119
Six months, rebased to 100: Elanco Animal Health against the median of its 20 peers (local-currency closes).

Elanco Animal Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.15B$4.71B$4.44B$4.42B$4.41B
Revenue growth—+6%0%0%—
Gross profit$2.33B$2.05B$1.91B$1.94B$1.97B
EBITDA$1.08B$932M$913M$1.02B$1.07B
Net income-$147M-$232M$338M-$1.23B-$78.0M
Free cash flow$408M$284M$394M$131M$315M
Capital expenditure$206M$276M$161M$154M$184M
Total debt$3.71B$4.14B$4.44B$5.92B$5.98B

Quarterly statements and history in the cockpit →

Elanco Animal Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%1093BMRNBBIOTECHHALONBIXKYMR002422KRYSPCVX1961701548BNTXSMMTTWST2269TXGUTHRCGONAXSMELAN6-month return →1-month return →
Up and to the right = strong over both horizons. Elanco Animal Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×1093BMRNTECHHALONBIX002422KRYS1961701548UTHRAXSMELANRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Elanco Animal Health is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%1093BMRNTECHHALONBIX002422KRYS19617015482269TXGUTHRELANGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Elanco Animal Health is the large dot.

Elanco Animal Health competitors and peer comparison

Head to head with its named competitors (ELAN vs ZTS vs MRK vs IDXX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Idexx Laboratories IDXX$55.0B+26%+12%32%42.9×29.0%

How Elanco Animal Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Elanco Animal Health against its 20 peers (data as of 18 Nov 2026)
MeasureELANPeer medianRank in peer set
1-month return+17.6%-8.2%2nd highest of 21
6-month return+28.1%+23.0%9th highest of 21
Distance from 52-week high-4.6%-24.3%2nd highest of 21
Revenue growth (TTM)+12.1%+25.6%6th lowest of 19
Operating margin7.6%15.8%8th lowest of 19
Forward P/E21.5×30.5×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)32.9%10.7%3rd most demanding of 13
Growth delivered (Del g)+7.6%+18.2%4th lowest of 13
Hurdle (Req g minus delivered)+25.3 pp-10.1 pp3rd most demanding of 13
ROIC minus cost of capital-8.8 pp-0.5 pp7th lowest of 18
EV / EBITDA15.3×16.4×4th cheapest of 11
Net debt / EBITDA3.0×-1.3×2nd most indebted of 11
Bond spread101 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a

Elanco Animal Health bonds and credit

Elanco Animal Health has 1 bond outstanding with $732M face value. The agencies rate it BB-; its bonds trade like BBB-. Weighted yield 5.49%, a spread of 101 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Elanco Animal Health's main competitors?
Named competitors: Zoetis (ZTS), Merck Animal Health (MRK), Idexx Laboratories (IDXX). The cockpit's measured peer set (industry) also includes Cspc Pharma (1093.HK), BioMarin Pharmaceutical (BMRN), BridgeBio Pharma (BBIO), Bio-Techne (TECH), Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX).
Is Elanco Animal Health expensive compared with its peers?
On forward p/e it trades at 21.5× against a peer median of 30.5×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Elanco Animal Health stock performed?
Over six months to 18 Nov 2026 the shares returned +28.1% against +23.0% for the median peer; over one year +24.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.